Spikevax (previously COVID‑19 Vaccine Moderna)
A Conditional Marketing Authorisation (CMA) has been granted in the EU for the product Spikevax (previously COVID‑19 Vaccine Moderna) to prevent coronavirus disease 2019 (COVID‑19) in people from 12 years of age.
Patient Information Leaflet
Patient Information Leaflet
Summary of Product Characteristics
Summary of Product Characteristics
Storage, Handling, Dosage and Administration
Storage, Handling, Dosage and Administration
2nd Dose Reminder Card
2nd Dose Reminder Card
Contact Moderna
8am-5pm WET – Mon - Fri
EMEAMedinfo@modernatx.com